Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow ZTS
Zoetis Inc. (ZTS) Net margin
Zoetis Inc.'s net margin over the twelve months to 30 June 2026 was 27.7%, down 0.5 percentage points from fiscal 2025 (28.2%). Over the past ten years it has ranged from 7.11% (fiscal 2015) to 28.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 28.2% | 1.37 |
| FY2024 | 26.9% | (0.57) |
| FY2023 | 27.4% | 1.27 |
| FY2022 | 26.2% | (0.04) |
| FY2021 | 26.2% | 1.66 |
| FY2020 | 24.5% | 0.58 |
| FY2019 | 24.0% | (0.56) |
| FY2018 | 24.5% | 8.24 |
| FY2017 | 16.3% | (0.52) |
| FY2016 | 16.8% | 9.69 |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 28.0% | 1.43 |
| Mar 2026 | 26.6% | 0.52 |
| Dec 2025 | 26.1% | (3.99) |
| Sep 2025 | 30.0% | 0.69 |
| 42 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| UTHR United Therapeutics Corporation compare | 41.6% |
| ZTS Zoetis Inc. | 27.7% |
| NBIX Neurocrine Biosciences, Inc. compare | 20.9% |
| HLN Haleon PLC Sponsored ADR compare | 13.8% |
| RDY Dr. Reddy's Laboratories Ltd compare | 9.81% |
| TAK Takeda Pharmaceutical Co. compare | 7.12% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 4.08% |
| VTRS Viatris Inc. compare | −2.79% |
| ELAN Elanco Animal Health Incorporated compare | −3.96% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.45% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement